

SOHO France

Congrès en hématologie

09-11 Octobre 2024


Sorbonne Université

Auditorium du CICSU

Patio 44-55 / Niveau Jussieu

4 place Jussieu

75 005 PARIS



En association avec

COMITÉ SCIENTIFIQUE

Présidente du Comité Scientifique

Mauricette MICHALLET (Hématologue, Centre Léon Bérard, Lyon)

Membres du Comité Scientifique

- Amine BELHABRI (Hématologue, Centre Léon Bérard, Lyon)
- Sylvain CHOQUET (Hématologue, Hôpital Pitié-Salpêtrière, Paris)
- Roch HOUOT (Hématologue, CHU de Rennes)
- Jean-Jacques KILADJIAN (Hématologue, Hôpital Saint-Louis, Paris)
- Xavier LELEU (Hématologue, CHU de Poitiers)
- François-Xavier MAHON (Hématologue, Institut Bergonié, Bordeaux)
- Anne-Sophie MICHALLET (Hématologue, Centre Léon Bérard, Lyon)
- Franck NICOLINI (Hématologue, Centre Léon Bérard, Lyon)
- Sophie PARK (Hématologue, CHU Grenoble Alpes)
- Christian RECHER (Hématologue, Institut Universitaire du Cancer de Toulouse)
- Philippe ROUSSELOT (Hématologue, Centre Hospitalier de Versailles, Le Chesnay)

NOS PARTENAIRES

Partenaires Platinium



Partenaires



PROGRAM

WEDNESDAY 09th OCTOBER 2024

08:30 - 09:00 a.m.....Opening

09:00 - 09:30 a.m.....Introduction

Mauricette MICHALLET (Hematology, Lyon)
Hagop KANTARJIAN (Oncology Hematology, Houston - USA)
Jean-Yves BLAY (Medical Oncology & General Manager Centre Léon Bérard, Lyon)
Claudio CERCHIONE (Hematology, Meldola - Italy)

09:30 - 11:00 a.m.....Session 1: MYELOPROLIFERATIVE NEOPLASMS

Chair: Jean-Jacques KILADJIAN (Hematology, Paris)

Machine Learning for the classification of patients with MPN: Gadget or earthquake? 20 min.
Daniel ROYSTON (Hematology, Oxford - UK)

Allogeneic cell transplantation for myelofibrosis: Who, why, when? 20 min.
Marie ROBIN (Hematology, Paris)

Immunotherapy, a new therapeutic avenue for MPNs 20 min.
Isabelle PLO-AZEVEDO (Hematology, Villejuif)

Discussion 30 min.

11:00 - 11:15 a.m.....Break 

11:15 a.m - 12:15 p.m.....TREATMENT OF MYELOFIBROSIS (MF) AND CHRONIC MYELOID LEUKAEMIA (CML) IN 2024

Chair: Franck-Emmanuel NICOLINI (Hematology, Lyon)



Current overview in Myelofibrosis treatment landscape and role of combotherapy
Jose-Miguel TORREGROSA-DIAZ (Hematology, Poitiers)

Towards a paradigm shift in the management of CML?
Franck-Emmanuel NICOLINI (Hematology, Lyon)

Discussion

12:15 - 01:15 p.mLunch Break

01:15 - 03:05 p.m.....Session 2: CHRONIC MYELOID LEUKEMIA

Chair: Franck-Emmanuel NICOLINI (Hematology, Lyon)

Molecular conditions of targeted therapy cessation in CP-CML 20 min.
Jean-Michel CAYUELA (Biological Hematology, Paris)

Targeted therapy cessation in adult CP-CML in the long-term: The STIM1 trial 20 min.
François-Xavier MAHON (Hematology, Bordeaux)

Targeted therapy cessation in pediatric CP-CML: Is it possible in this setting? 20 min.
Frédéric MILLOT (Pediatric Hematology, Poitiers)

RNASEq and targeted therapy cessation in CP-CML 20 min.
Vincent ALCAZER (Hematology, Pierre Bénite)

Discussion 30 min.

03:05 - 03:20 p.m.....Break 

03:20 - 05:30 p.m.....	Session 3: MULTIPLE MYELOMA Chair: Xavier LELEU (Hematology, Poitiers) Multiple myeloma: Best of biology Anais SCHAVGOULIDZE (Biological Hematology, Toulouse)	20 min.
	NDMM NTE Xavier LELEU (Hematology, Poitiers)	20 min.
	NDMM TE Aurore PERROT (Hematology, Toulouse)	20 min.
	RRMM relapse early but not only Cyrille TOUZEAU (Hematology, Nantes)	20 min.
	Best of 2024 Arthur BOBIN (Hematology, Poitiers)	20 min.
	Discussion	30 min.

THURSDAY 10th OCTOBER 2024

08:30 - 09:00 a.m.....Opening

09:00 - 10:30 a.m.....	Session 4: MYELODYSPLASTIC SYNDROMES Chair: Sophie PARK (Hematology, Grenoble) Germline mutations: How to manage the constitutional in practice in the context of MDS? Marie SEBERT (Hematology, Paris)	20 min.
	VEXAS syndrome in 2024 Olivier KOSMIDER (Biological Hematology, Paris)	20 min.
	Updates in the treatment of low-risk MDS Sophie PARK (Hematology, Grenoble)	20 min.
	Discussion	30 min.

10:30 - 10:45 a.m.....Break 

10:45 a.m - 12:35 p.m....	Session 5: LYMPHOMAS Chair: Sylvain CHOQUET (Hematology, Paris) Clonal Hematopoiesis and lymphoid malignancies Olivier KOSMIDER (Biological Hematology, Paris)	20 min.
	Grey Zone type NHL Clémentine SARCOZY (Hematology, Paris)	20 min.
	Classical Hodgkin lymphoma: National recommendations Guillaume MANSON (Hematology, Rennes)	20 min.
	Hepato-splenic T cell lymphoma David SIBON (Hematology, Paris) Marie PARRENS (Pathology, Pessac)	20 min.
	Discussion	30 min.

12:35 p.m - 12:55 p.m....Oral Abstract

12:55 - 01:55 p.m.....Lunch Break & Poster Walk

01:55 - 02:55 p.m.....ROLE OF MOLECULAR BIOLOGY IN TARGETED THERAPIES ACCORDING TO INNOVATIVE COMBINATIONS IN AML

Chairs: Stéphane DE BOTTON (Hematology, Villejuif)

Arnaud PIGNEUX (Hematology, Bordeaux)



Onco-theranostic approach in fit and unfit patients with newly diagnosed AML:

Towards a combination of targeted therapies

Pierre-Yves DUMAS (Hematology, Bordeaux)

What role for the molecularist in the management of patients with AML?

Olivier KOSMIDER (Biological Hematology, Paris)

Discussion

02:55 - 04:45 p.m.....Session 6: ACUTE LYMPHOBLASTIC LEUKEMIA

Chair: Philippe ROUSSELOT (Hematology, Le Chesnay)

The biology of ABL-class ALL

Anita RIJNEVELD (Hematology, Rotterdam - Netherlands)

20 min.

MRD in Ph+ ALL

Emmanuelle CLAPPIER (Biological Hematology, Paris)

20 min.

Inotuzumab first line in B-ALL

Philippe ROUSSELOT (Hematology, Le Chesnay)

20 min.

Biological landscape of T-ALL

Vahid ASNAFI (Hematology, Paris)

20 min.

Discussion

30 min.

04:45 - 05:05 p.m.....Break 

05:05 - 06:55 p.m.....Session 7: ACUTE MYELOID LEUKEMIA

Chairs: Arnaud Pigneux (Hematology, Bordeaux)

Christian Recher (Hematology, Toulouse)

Role of host autophagy in acute myeloid leukemia metabolism and therapeutic resistance

Laura POILLET (Cancer Biology, Toulouse)

20 min.

Mechanism of action of Menin inhibitors and results of clinical trials

Raphael ITZYKSON (Hematology, Paris)

20 min.

Real world use of Azacitidine/Venetoclax in AML: South East and South West registries

Gaspar ASPAS REQUENA (Hematology, Clermond-Ferrant)

Pierre-Yves DUMAS (Hematology, Bordeaux)

20 min.

Is there still a place for intensive chemotherapy in the treatment of older AML in USA

Courtney DINARDO (Oncology, Houston - USA)

20 min.

Discussion

30 min.

FRIDAY 11th OCTOBER 2024

08:30 - 09:00 a.mOpening

09:00 - 10:50 a.mSession 8: CHRONIC LYMPHOCYTIC LEUKEMIA

Chair: Anne-Sophie MICHALLET (Hematology, Lyon)

Debate: IV vs G+ venetoclax in first-line CLL 40 min.
Pierre FEUGIER (Hematology, Nancy) vs Emmanuelle FERRANT (Hematology, Lyon)

Towards targeted therapy treatment in first-line WM 20 min.
Damien ROOS-WEIL (Hematology, Paris)

Relapsing: iBTK for everyone? 20 min.
Anne QUINQUENEL (Hematology, Reims)

Discussion 30 min.

10:50 - 11:10 a.mOral Abstract

11:10 - 11:30 a.mBreak 

11:30 - 12:30 p.mCLL IN HIGH-RISK PATIENTS: INFLUENCE OF BIOLOGY ON CLINICAL PRACTICE

Chair: Pierre FEUGIER (Hematology, Nancy)

Biology - TP53 pathway abnormalities in CLL
Grégory LAZARIAN (Hematology, Paris)

What treatment for high-risk CLL patients in 1L?
Pierre FEUGIER (Hematology, Nancy)

What impact do mutations have on the BTKi resistance?
Florence NGUYEN-KHAC (Hematology, Paris)

Discussion



12:30 p.m - 01:30 p.mLunch Break

01:30 - 01:40 p.mAward Ceremony - Call for Abstract

01:40 - 03:30 p.mSession 9: CAR T-CELLS

Chair: Marion ALCANTARA (Hematology, Saint-Cloud)

Introduction by Marion ALCANTARA 10 min.

CAR T-cells in specific populations (CNS+, PTLN, HIV+) 20 min.
Sylvain CHOQUET (Hematology, Paris)

Mechanisms of resistance to CAR T-cell therapy 20 min.
Jean LEMOINE (Hematology, Pennsylvania - USA)

CAR T-cell in T-cell malignancies 20 min.
André BARUCHEL (Hematology, Paris)

CAR T-cell in autoimmune diseases 20 min.
Alain LESCOAT (Internal medicine, Rennes)

Discussion 20 min.

03:30 - 03:40 p.mClosing Remarks